Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study

Acadia Pharmaceuticals NASDAQ:ACAD said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions in patients with the condition.Shares of the drugmaker fell about 12% in premark…